Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Vanguard Total International Stock Index Fund ETF trades at $84.59. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Vanguard Total International Stock Index Fund ETF pays none, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | VXUS | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Sector/Thematic |
52-Week High | $812.27 | $87.06 |
52-Week Low | $545.46 | $68.24 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
VXUS trades at $83.07, down 0.36% with a bearish technical signal from moving averages. The ETF provides diversified international exposure to over 8,700 non-U.S. stocks across developed and emerging markets. Recent institutional buying activity includes Greenwood Gearhart increasing its position by 45.8% in Q1 2026. Technical indicators show neutral oscillators but bearish momentum with support at $82 and resistance at $84.
The outlook remains cautious due to global economic uncertainty, though VXUS offers diversification benefits for U.S.-centric portfolios. Key risks include currency fluctuations and emerging market volatility. Analyst sentiment is mixed with some recommending international diversification while others caution about growth/inflation dynamics in global markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
